Andrew Gallimore is a computational neurobiologist, pharmacologist, chemist, and writer who has been interested in the neural basis of psychedelic drug action for many years and is the author of a number of articles and research papers on the powerful psychedelic drug, N,N-dimethyltryptamine (DMT) and its effects on the brain and consciousness.

In 2015, he collaborated with DMT pioneer Dr. Rick Strassman, author of DMT: The Spirit Molecule, to develop a pharmacokinetic model of DMT as the basis of a target-controlled intravenous infusion protocol for extended journeys in the bizarre worlds to which DMT gates access.

His current interests focus on DMT and other psychedelic molecules as tool for gating access to otherwise inaccessible subjective worlds, their neuroscientific underpinning, and their possible ontological and metaphysical implications. He currently lives and works in Tokyo.